CMS June 2025 Call on Medicare Drug Price Negotiation & Inflation Rebate
Relevant to: Drug Manufacturer Module Enhancements, Drug Pricing
Each week, we scan the latest CMS memos to find the most important ones that apply for PACE programs. Below is a summary of what you need to know.
Disclaimer: The content provided on this site is a summary for informational purposes only, and Grane PBM, Inc. assumes no liability for any errors or omissions in the site’s content. The information does not constitute legal or regulatory advice or replace the original CMS memo. Readers are advised to consult the CMS memo in its entirety and to verify information independently before making any decisions based on this information.
Click here to read the complete memo from CMS.
Introduction
The Department of Health & Human Services, through the Centers for Medicare & Medicaid Services (CMS), has announced a pivotal call for drug manufacturers on implementing the Medicare Drug Price Negotiation Program. Scheduled for June 24, 2025, the call aims to foster open communication and offers a platform for manufacturers to engage with CMS on key issues, particularly around the Medicare Transaction Facilitator and inflation rebate reports. Registration is required by June 20, 2025, with details on the session to follow.
Key Dates and Deadlines
- Next call: June 24, 2025, from 1:00 – 2:30 PM EST
- Registration closes: June 20, 2025, at 5:00 PM EST
PACE Compliance
While the memo is directed at drug manufacturers and focuses on the implementation of the Medicare Drug Price Negotiation Program, it is important for PACE (Programs of All-Inclusive Care for the Elderly) organizations to be aware of any updates and changes in Medicare drug pricing policies, as these may indirectly affect them.
Although there aren’t specific directives for PACE organizations in this memo, it is crucial for PACE plans to maintain awareness of changes in drug pricing and manufacturer negotiations that may impact the drugs covered and their pricing. This can influence budgets and the overall costs for providing care to participants.
PACE organizations should:
– Review any changes in the Medicare Drug Price Negotiation Program and Inflation Rebate programs that could affect the costs of medications for their participants.
– Stay informed of updates from CMS and consider attending relevant calls or forums to gather information that could influence their drug purchasing decisions.
– Ensure that their drug rebate and pricing models comply with Medicare guidelines to avoid potential issues with drug reimbursement and coverage under the PACE program.
While this specific memo does not detail any PACE compliance requirements, staying informed and engaged with CMS updates is good practice for ensuring compliance with Medicare-related policies.
Required Actions
1. Submit questions for the June 24th call on Medicare Drug Price Negotiation and Inflation Rebate programs to IRARebateandNegotiation@cms.hhs.gov with the subject line ‘6/24 Discussion Question – Manufacturer’.
2. Register for the call by clicking the provided link by Friday, June 20 at 5:00 PM EST. Ensure you have access to the email used for registration as the Zoom link and agenda will be sent there.
3. If you have issues with HPMS access or your P#, contact the HPMS Access Help Desk at hpms_access@cms.hhs.gov for support.
FAQs
- “What is the Medicare Drug Price Negotiation Program?”
- “How can drug manufacturers participate in the CMS call on June 24, 2025?”
- “Who should drug manufacturers contact for registering issues with HPMS?”
- “What topics will be covered in the CMS call regarding the Medicare Drug Price Negotiation Program?”
- “How can manufacturers submit questions for the CMS call?”
